title: [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
abstract: Anti-TNF alpha are immunomodulatory treatments prescribed for some rheumatologic inflammatory diseases (ex: spondylarthropathy, rheumatoid polyarthritis). The randomised studies suggested that anti-TNF alpha therapy is associated with an overall risk of infectious diseases. The results of the observational studies are more reassuring. In this article, we will describe some results of theses studies and propose some practical recommendations in use of the anti-TNF alpha therapy.
authors.affiliation: Service de rhumatologie, Département de l'appareil locomoteur, CHUV, 1011 Lausanne. melanie.faucherre@chuv.ch
authors.forename: M
authors.initials: M
authors.lastname: Faucherre
authors.forename: B
authors.initials: B
authors.lastname: Pazar
authors.forename: A
authors.initials: A
authors.lastname: So
authors.forename: B
authors.initials: B
authors.lastname: Aubry-Rozier
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control; D012216:Rheumatic Diseases / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha